These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
417 related articles for article (PubMed ID: 32607760)
1. Involvement of ROS/NLRP3 Inflammasome Signaling Pathway in Doxorubicin-Induced Cardiotoxicity. Wei S; Ma W; Li X; Jiang C; Sun T; Li Y; Zhang B; Li W Cardiovasc Toxicol; 2020 Oct; 20(5):507-519. PubMed ID: 32607760 [TBL] [Abstract][Full Text] [Related]
2. Trastuzumab potentiates doxorubicin-induced cardiotoxicity via activating the NLRP3 inflammasome in vivo and in vitro. Wei S; Ma W; Yang Y; Sun T; Jiang C; Liu J; Zhang B; Li W Biochem Pharmacol; 2023 Aug; 214():115662. PubMed ID: 37331637 [TBL] [Abstract][Full Text] [Related]
3. MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis. Zhang L; Jiang YH; Fan C; Zhang Q; Jiang YH; Li Y; Xue YT Biomed Pharmacother; 2021 Nov; 143():112133. PubMed ID: 34474337 [TBL] [Abstract][Full Text] [Related]
4. Hyperoside prevents doxorubicin-induced cardiotoxicity by inhibiting NOXs/ROS/NLRP3 inflammasome signaling pathway. Wei S; Ma W; Jiang C; Liu J; Liu J; Zhang B; Li W Phytother Res; 2023 Sep; 37(9):4196-4209. PubMed ID: 37246409 [TBL] [Abstract][Full Text] [Related]
5. The protective effect of thiolutin on doxorubicin-induced H9c2 cardiomyocyte injury. Cai W; Teng T; Wang X; Li B; Gu X; Zhou Y J Toxicol Sci; 2023; 48(8):469-479. PubMed ID: 37532580 [TBL] [Abstract][Full Text] [Related]
6. Exogenous 8-hydroxydeoxyguanosine attenuates doxorubicin-induced cardiotoxicity by decreasing pyroptosis in H9c2 cardiomyocytes. Hwang S; Kim SH; Yoo KH; Chung MH; Lee JW; Son KH BMC Mol Cell Biol; 2022 Dec; 23(1):55. PubMed ID: 36517746 [TBL] [Abstract][Full Text] [Related]
7. Dopamine D1 receptor alleviates doxorubicin-induced cardiac injury by inhibiting NLRP3 inflammasome. Liu J; Jin Y; Wang B; Wang Y; Zuo S; Zhang J Biochem Biophys Res Commun; 2021 Jul; 561():7-13. PubMed ID: 33992835 [TBL] [Abstract][Full Text] [Related]
9. Lipopolysaccharide (LPS) Aggravates High Glucose- and Hypoxia/Reoxygenation-Induced Injury through Activating ROS-Dependent NLRP3 Inflammasome-Mediated Pyroptosis in H9C2 Cardiomyocytes. Qiu Z; He Y; Ming H; Lei S; Leng Y; Xia ZY J Diabetes Res; 2019; 2019():8151836. PubMed ID: 30911553 [TBL] [Abstract][Full Text] [Related]
10. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. Luo B; Li B; Wang W; Liu X; Xia Y; Zhang C; Zhang M; Zhang Y; An F PLoS One; 2014; 9(8):e104771. PubMed ID: 25136835 [TBL] [Abstract][Full Text] [Related]
11. Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1. Sun Z; Lu W; Lin N; Lin H; Zhang J; Ni T; Meng L; Zhang C; Guo H Biochem Pharmacol; 2020 May; 175():113888. PubMed ID: 32112883 [TBL] [Abstract][Full Text] [Related]
12. Hydrogen-Rich Saline Attenuated Subarachnoid Hemorrhage-Induced Early Brain Injury in Rats by Suppressing Inflammatory Response: Possible Involvement of NF-κB Pathway and NLRP3 Inflammasome. Shao A; Wu H; Hong Y; Tu S; Sun X; Wu Q; Zhao Q; Zhang J; Sheng J Mol Neurobiol; 2016 Jul; 53(5):3462-3476. PubMed ID: 26091790 [TBL] [Abstract][Full Text] [Related]
13. ALDH2 Overexpression Alleviates High Glucose-Induced Cardiotoxicity by Inhibiting NLRP3 Inflammasome Activation. Cao R; Fang D; Wang J; Yu Y; Ye H; Kang P; Li Z; Wang H; Gao Q J Diabetes Res; 2019; 2019():4857921. PubMed ID: 31871948 [TBL] [Abstract][Full Text] [Related]
14. The beneficial effects of reducing NLRP3 inflammasome activation in the cardiotoxicity and the anti-cancer effects of doxorubicin. Maayah ZH; Takahara S; Dyck JRB Arch Toxicol; 2021 Jan; 95(1):1-9. PubMed ID: 32852568 [TBL] [Abstract][Full Text] [Related]
15. Honokiol antagonizes doxorubicin‑induced cardiomyocyte senescence by inhibiting TXNIP‑mediated NLRP3 inflammasome activation. Huang PP; Fu J; Liu LH; Wu KF; Liu HX; Qi BM; Liu Y; Qi BL Int J Mol Med; 2020 Jan; 45(1):186-194. PubMed ID: 31746354 [TBL] [Abstract][Full Text] [Related]
16. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Quagliariello V; De Laurentiis M; Rea D; Barbieri A; Monti MG; Carbone A; Paccone A; Altucci L; Conte M; Canale ML; Botti G; Maurea N Cardiovasc Diabetol; 2021 Jul; 20(1):150. PubMed ID: 34301253 [TBL] [Abstract][Full Text] [Related]
17. Nicotinamide mononucleotide attenuates doxorubicin-induced cardiotoxicity by reducing oxidative stress, inflammation and apoptosis in rats. Wan Y; He B; Zhu D; Wang L; Huang R; Zhu J; Wang C; Gao F Arch Biochem Biophys; 2021 Nov; 712():109050. PubMed ID: 34610336 [TBL] [Abstract][Full Text] [Related]
18. Gypenosides improve diabetic cardiomyopathy by inhibiting ROS-mediated NLRP3 inflammasome activation. Zhang H; Chen X; Zong B; Yuan H; Wang Z; Wei Y; Wang X; Liu G; Zhang J; Li S; Cheng G; Wang Y; Ma Y J Cell Mol Med; 2018 Sep; 22(9):4437-4448. PubMed ID: 29993180 [TBL] [Abstract][Full Text] [Related]